Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.39 |
| ▸ | CNR2 | P34972 | 4/20 | 0.38 |
| ▸ | METAP2 | P50579 | 2/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.36 |
| ▸ | LCAT | P04180 | 3/20 | 0.36 |
| ▸ | CDK4 | P11802 | 3/20 | 0.36 |
| ▸ | PRKDC | P78527 | 1/20 | 0.36 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20249165 | 1.00 | TRPV1 (0.42) | TRPV1HRH4CNR2METAP2CHRNB2 | |
| SCHEMBL20249356 | 1.00 | TRPV1 (0.42) | TRPV1HRH4CNR2METAP2CHRNB2 | |
| SCHEMBL20249293 | 0.91 | SMPD3 (0.42) | TRPV1CDK4CDK6 | |
| SCHEMBL20249149 | 0.91 | SMPD3 (0.42) | TRPV1CDK4CDK6 | |
| SCHEMBL20249302 | 0.91 | SMPD3 (0.42) | TRPV1CDK4CDK6 | |
| SCHEMBL20249147 | 0.91 | LMNA (0.40) | TRPV1LCAT | |
| SCHEMBL20249350 | 0.87 | KMT2A (0.38) | TRPV1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL20249327 | 0.83 | HRH4 (0.39) | HRH4CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL20249322 | 0.83 | HRH4 (0.39) | HRH4CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL20249347 | 0.81 | PTGER4 (0.40) | HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | TRPV1 3672/4885HRH4 1763/4885CNR2 2055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.